Bioreversion and oral bioavailability of the L-valine dipeptide ester prodrug of acyclovir, val-valacyclovir, in Sprague-Dawley rats

Clinical Research and Regulatory Affairs

Volumn 21, Issue 1, 2004, Pages 67-79

  Majumdar, Soumyajit ^a   Duvvuri, Sridhar ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Acyclovir; Bioavailability; SD rats; Stability; Val valacyclovir; Valacyclovir

Indexed keywords

ACICLOVIR; PRODRUG; UNCLASSIFIED DRUG; VALACICLOVIR; VALVALACICLOVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG STABILITY; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE CELL; INTESTINE HOMOGENATE; LIVER HOMOGENATE; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NONHUMAN; RAT; TISSUE HOMOGENATE;

EID: 3242679881     PISSN: 10601333     EISSN: None     Source Type: Journal    
DOI: 10.1081/CRP-120030033     Document Type: Article

References (24)

1. Leung DT, Sacks SL. Current treatment options to prevent perinatal transmission of herpes simplex virus. Expert Opin Pharmacother 2003; 4(10):1809-1819.
2. DeJesus E, Wald A, Warren T, Schacker TW, Trottier S, Shahmanesh M, Hill JL, Brennan CA. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188(7): 1009-1016.
3. Wu JJ, Brentjens MH, Torres G, Yeung-Yue K, Lee P, Tyring SK. Valacyclovir in the treatment of herpes simplex, herpes zoster, and other viral infections. J Cutan Med Surg 2003; 10227(5):372-381.
4. Eisen D, Essell J, Broun ER, Sigmund D, DeVoe M. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue theraphy. Bone Marrow Transplant 2003; 31(1):51-55.
5. Phan DD, Chin-Hong P, Lin ET, Anderle P, Sadee W, Guglielmo BJ. Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor. Antimicrob Agents Chemother 2003; 47(7):2351-2353.
6. Perry CM, Faulds D. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996; 52(5):754-772.
7. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved theraphy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39(7):1546-1553.
8. Hoglund M, Ljungman P, Weller S. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J Antimicrob Chemother 2001; 47(6):855-861.
9. Steingrimsdottir H, Gruber A, Palm C, Grimfors G, Kalin M, Eksborg S. Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotheraphy. Antimicrob Agents Chemother 2000; 44(1):207-209.
10. Sawada K, Terada T, Saito H, Hashimoto Y, Inui KI. Recognition of L-amino acid ester compounds by rat peptide transporters PEPT1 and PEPT2. J Pharmacol Exp Ther 1999; 291(2):705-709.
11. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, Oh DM, Sadee W, Amidon GL. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res 1998; 15(18):1154-1159.
12. Sinko PJ, Balimane PV. Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats. Biopharm Drug Dispos 1998; 19(4):209-217.
13. Han HK, Oh DM, Amidon GL. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPTI cells overexpressing a human peptide tranporter. Pharm Res 1998; 15(9):1382-1389.
14. Anand BS, Patel J, Mitra AK. Interactions of the dipeptide ester prodrugs of acyclovir with the intestinal oligopeptide transporter: competitive inhibition of glycylsarcosine transport in human intestinal cell line-Caco-2. J Pharmacol Exp Ther 2003; 304(2):781-791.
15. Guo A, Hu P, Balimane PV, Leibach FH, Sinko PJ. Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line. J Pharmacol Exp Ther 1999; 289(1):448-454.
16. Kim I, Chu XY, Kim S, Provoda CJ, Lee KD, Amidon GL. Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J Biol Chem 2003; 278(28):25348-25356.
17. Burnette TC, Harrington JA, Reardon JE, Merrill BM, de Miranda P. Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir. J Biol Chem 1995; 270(26):15827-15831.
18. Anand B, Nashed Y, Mitra A. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: bioreversion, antiviral activity and transport across rabbit cornea. Curr Eye Res 2003; 26(3-4):151-163.
19. Fish DN, Viadurri VA, Deeter RG. Stability of valacyclovir hydrochloride in extemporaneously prepared oral liquids. Am J Health-Syst Pharm 1999; 56(19):1957-1960.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
21. Snoeck R. Antiviral therapy of herpes simplex. Int J Antimicrob Agents 2000; 16(2):157-159.
22. Balfour HH Jr. Current management of varicella zoster virus infections. J Med Virol 1993; Suppl 1:74-81.
23. Pagano JS, Sixbey JW, Lin JC. Acyclovir and epstein-barr virus infection. J Antimicrob Chemother 1983; 12 Suppl B:113-121.
24. Burnette TC, de Miranda P. Metabolic disposition of the acyclovir prodrug valaciclovir in the rat. Drug Metab Dispos 1994; 22(1):60-64.